"Since its inception, AYTU has evolved into an acquisition-based company that puts a priority on strategic in-licensing. It also has a strong drug development pipeline that focuses on rare genetic diseases called vascular Ehlers-Danlos Syndrome (vEDS). Currently, it’s testing a potential treatment – AR101/enzastaurin, in an attempt to reduce morbidity and lengthen life. While testing can take a substantial amount of time, having a steady flow of research in a pipeline is always encouraging for biotech investors to see."
Quote Source: 7 Top Penny Stocks to Watch Right Now With Big News